Top Markets
#1 QuantixAI QuantixAI +102.83%
#2 MetaDAO MetaDAO +25.95%
#3 Pons Pons +24.24%
#4 龙虾 (Lobster) 龙虾 (Lobster) +24.22%
#5 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +23.90%
#6 Rain Rain +21.62%
#7 Bedrock Bedrock +21.46%
#8 Ontology Gas Ontology Gas +20.44%
#9 SPX6900 SPX6900 +18.54%
#10 Prom Prom +17.73%
Coin of the day
QuantixAI QuantixAI
設定
言語
日本
通貨
USD
テーマ
Grifols, S.A. Grifols, S.A.

Grifols, S.A.

GRF
株式のランク #2542
Grifols, S.A., a Spanish company established in 1940 and headquartered in... Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
株価
$11.91
時価総額
$8.11B
変化（1日）
1.67%
変化（1年）
-16.23%
国
ES
取引 Grifols, S.A. (GRF)

カテゴリー

Healthcare
Grifols, S.A.（GRF）のP/E比率
2026 時点のP/E比率 TTM 0
Grifols, S.A. の最新の財務報告および株価によると、現在の P/E (TTM) は 0 です。2026 年末時点での P/E は 0 でした。
Grifols, S.A. の P/E 比率の履歴（2026 〜 2026）
各年末のP/E比率
年 P/E比率 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社のP/E比率
企業 P/E比率 P/E比率の差 国
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 39.54 -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 30.10 -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 70.28 -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 22.25 -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 107.81 -
US
P/E比率の読み方

株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。